Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Inc. is trading at $24.18, down 0.70% on the session. The 50 day average sits at $23.85 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 51.6, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $22.63 with resistance near $24.68, so that band frames the current range. Average daily movement is roughly $1.02, or about 4.2% of the share price, which is what any stop placement has to allow for. The overall health score of 68 out of 100 combines a trend score of 75, momentum of 72 and a risk score of 52.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.